ReviewJournal of hematology & oncology2012
Novel targeted agents for gastric cancer.
Review in Journal of hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.American journal of clinical pathology · 2016Guideline
- Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.Clinical pharmacokinetics · 2017Trial
- Prevalence of HER2 expression and its association with clinicopathological parameters in gastric and gastroesophageal junction adenocarcinoma: A 10?year experience of an academic center.Molecular and clinical oncology · 2025Article
- Exosomal miR‑3681‑3p from M2‑polarized macrophages confers cisplatin resistance to gastric cancer cells by targeting MLH1.Molecular medicine reports · 2025Article
- Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma.Frontiers in oncology · 2022Article
- Significant function and research progress of biomarkers in gastric cancer.Oncology letters · 2020Review
- Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.Journal of hematology & oncology · 2019Article
- Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer.OncoTargets and therapy · 2019Article
- Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.Thoracic cancer · 2018Article
- Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study.Scientific reports · 2018Article
- FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.Cancer research and treatment · 2018Article
- Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.Molecular and clinical oncology · 2017Article
- Article
- Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.BMC cancer · 2016Article
- The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas.Journal of hematology & oncology · 2015Article
- Causes and consequences of microsatellite instability in gastric carcinogenesis.World journal of gastroenterology · 2014Review
- Pathogenetic mechanisms in gastric cancer.World journal of gastroenterology · 2014Review
- Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.World journal of surgical oncology · 2014Article
- Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells.World journal of gastroenterology · 2014Article
- Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer.BMC cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contemporary advancements have had little impact on the treatment of gastric cancer (GC), the world's second highest cause of cancer death. Agents targeting human epidermal growth factor receptor mediated pathways have been a common topic of contemporary cancer research, including monoclonal antibodies (mAbs) and receptor tyrosine kinase inhibitors (TKIs). Trastuzumab is the first target agent evidencing improvements in overall survival in HER2-positive (human epidermal growth factor receptor 2) gastric cancer patients. Agents targeting vascular epithelial growth factor (VEGF), mammalian target of rapamycin (mTOR), and other biological pathways are also undergoing clinical trials, with some marginally positive results. Effective targeted therapy requires patient selection based on predictive molecular biomarkers. Most phase III clinical trials are carried out without patient selection; therefore, it is hard to achieve personalized treatment and to monitor patient outcome individually. The trend for future clinical trials requires patient selection methods based on current understanding of GC biology with the application of biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.